Previous issue | Volume 89 | ESPE2018 | Next issue

57th Annual ESPE

Athens, Greece
27 Sep 2018 - 29 Sep 2018

Card image cap
ESPE 2018 57th European Society for Paediatric Endocrinology Annual Meeting 27-29 September 2018 Athens, Greece

Novel Advances & Controversies in Paediatric Endocrinology

Cell engineering for treatment of diabetes

hrp0089na2.1 | Cell engineering for treatment of diabetes | ESPE2018

Stem Cells as a Source of Beta Cells

Zulewski Henryk

The ultimate therapy for type 1 diabetes is the replacement of the lost insulin producing cells instead of the actual life-saving but imperfect substitution of insulin. The isolation of embryonic stem cells (ESC) and later the reprogramming of somatic cells into induced pluripotent stem cells (iPSC) raised enormous hopes for cell based therapies in diabetes type 1. The first important stage in the differentiation process of ESC/iPSC is the generation of definite endoderm that ...

hrp0089na2.2 | Cell engineering for treatment of diabetes | ESPE2018

Induction of Pancreatic Beta-Cell Neogenesis

Collombat Patrick

Background: The recent discovery that genetically-modified pancreatic alpha-cells can regenerate and convert into beta-like cells in vivo holds great promise for diabetes research. However, to eventually translate these findings to human, it is crucial to discover compounds with similar activities.Results: We recently identified GABA as an inducer of alpha-to-beta-like cell conversion in vivo. This conversion induces alpha-cell replacement mechanisms thr...